For instance, NPM1-mutated AML, as the largest subgroup in this novel classification, had variable clinical outcomes influenced by the presence of concurrent mutations such as FLT3, DNMT3A, NRAS, IDH, PTPN11, or chromatin-spliceosome mutations. This evidence concerns the gene FLT3 and acute myeloid leukemia.